Citrate and albumin facilitate transferrin iron loading in the presence of phosphate.

Labile plasma iron (LPI) is redox active, exchangeable iron that catalyzes the formation of reactive oxygen species. Serum transferrin binds iron in a non-exchangeable form and delivers iron to cells. In several inflammatory diseases serum LPI increases but the reason LPI forms is unknown. This work evaluates possible pathways leading to LPI and examines potential mediators of apo transferrin iron loading to prevent LPI. Previously phosphate was shown to inhibit iron loading into apo transferrin by competitively binding free Fe3+. The reaction of Fe3+ with phosphate produced a soluble ferric phosphate complex. In this study we evaluate iron loading into transferrin under physiologically relevant phosphate conditions to evaluate the roles of citrate and albumin in mediating iron delivery into apo transferrin. We report that preformed Fe3+-citrate was loaded into apo transferrin and was not inhibited by phosphate. A competition study evaluated reactions when Fe3+ was added to a solution with citrate, phosphate and apo transferrin. The results showed citrate marginally improved the delivery of Fe3+ to apo transferrin. Studies adding Fe3+ to a solution with phosphate, albumin and apo transferrin showed that albumin improved Fe3+ loading into apo transferrin. The most efficient Fe3+ loading into apo transferrin in a phosphate solution occurred when both citrate and albumin were present at physiological concentrations. Citrate and albumin overcame phosphate inhibition and loaded apo transferrin equal to the control of Fe3+ added to apo transferrin. Our results suggest a physiologically important role for albumin and citrate for apo transferrin iron loading.

[1]  H. Franch,et al.  Getting to the Meat of the Matter: Beyond Protein Supplementation in Maintenance Dialysis , 2009, Seminars in dialysis.

[2]  D. Torre,et al.  Serum Citrate Levels, Haptoglobin Haplotypes and Transferrin Receptor (CD71) in Patients With HIV-1 Infection , 2002, Infection.

[3]  André M. N. Silva,et al.  Influence of non-enzymatic post-translation modifications on the ability of human serum albumin to bind iron. Implications for non-transferrin-bound iron speciation. , 2009, Biochimica et biophysica acta.

[4]  R. J. Hilton,et al.  The ferroxidase center is essential for ferritin iron loading in the presence of phosphate and minimizes side reactions that form Fe(III)-phosphate colloids , 2011, BioMetals.

[5]  D. C. Harris,et al.  Facilitation of Fe(II) antoxidation by Fe(III) complexing agents , 1973 .

[6]  Xiaole Kong,et al.  Glutathione: a key component of the cytoplasmic labile iron pool , 2011, BioMetals.

[7]  C. Winterbourn,et al.  Radical-driven Fenton reactions: studies with paraquat, adriamycin, and anthraquinone 6-sulfonate and citrate, ATP, ADP, and pyrophosphate iron chelates. , 1987, Archives of biochemistry and biophysics.

[8]  J. Himmelfarb,et al.  Albumin is the major plasma protein target of oxidant stress in uremia. , 2001, Kidney international.

[9]  P. Brissot,et al.  Non-transferrin bound iron: a key role in iron overload and iron toxicity. , 2012, Biochimica et biophysica acta.

[10]  E. Frieden,et al.  A micromethod for the determination of ferroxidase (ceruloplasmin) in human serums. , 1967, Clinical chemistry.

[11]  B. Kestenbaum,et al.  Serum phosphate levels and mortality risk among people with chronic kidney disease. , 2005, Journal of the American Society of Nephrology : JASN.

[12]  M. Schlabach,et al.  The reaction of ferric salts with transferrin. , 1973, The Journal of biological chemistry.

[13]  R. Løvstad Interaction of serum albumin with the Fe(III)-citrate complex. , 1993, The International journal of biochemistry.

[14]  N. Vaziri,et al.  Iatrogenic Iron Overload in Dialysis Patients at the Beginning of the 21st Century , 2016, Drugs.

[15]  David G Levitt,et al.  Human serum albumin homeostasis: a new look at the roles of synthesis, catabolism, renal and gastrointestinal excretion, and the clinical value of serum albumin measurements , 2016, International journal of general medicine.

[16]  A. Bush,et al.  A comparison of ceruloplasmin to biological polyanions in promoting the oxidation of Fe(2+) under physiologically relevant conditions. , 2014, Biochimica et biophysica acta.

[17]  Z. Cabantchik Labile iron in cells and body fluids: physiology, pathology, and pharmacology , 2014, Front. Pharmacol..

[18]  Tyson Terpstra,et al.  The thermodynamic and binding properties of the transferrins as studied by isothermal titration calorimetry. , 2012, Biochimica et biophysica acta.

[19]  P. Brissot,et al.  Quantification of non-transferrin-bound iron in the presence of unsaturated transferrin. , 1999, Analytical biochemistry.

[20]  T. T. Nielsen Plasma citrate during submaximal and intermittent supramaximal exercise. , 1978, Scandinavian journal of clinical and laboratory investigation.

[21]  Elizabeth C. Theil,et al.  Fe(III).ATP complexes. Models for ferritin and other polynuclear iron complexes with phosphate. , 1985, The Journal of biological chemistry.

[22]  A. Garg,et al.  Chronic kidney disease and mortality risk: a systematic review. , 2006, Journal of the American Society of Nephrology : JASN.

[23]  C. Zoccali Cardiorenal risk as a new frontier of nephrology: research needs and areas for intervention. , 2002, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[24]  M. Wolf,et al.  Roles of phosphate and fibroblast growth factor 23 in cardiovascular disease , 2014, Nature Reviews Nephrology.

[25]  B. Stockwell,et al.  The role of iron and reactive oxygen species in cell death. , 2014, Nature Chemical Biology.

[26]  R. Harkness,et al.  ATP, ADP and AMP in plasma from peripheral venous blood. , 1984, Clinica chimica acta; international journal of clinical chemistry.

[27]  R. Boyer,et al.  Iron incorporation into apoferritin. The role of apoferritin as a ferroxidase. , 1986, The Journal of biological chemistry.

[28]  M. Kruszewski,et al.  Further evidence that oxidative stress may be a risk factor responsible for the development of atherosclerosis. , 2001, Free radical biology & medicine.

[29]  Z. Cabantchik,et al.  The assessment of serum nontransferrin-bound iron in chelation therapy and iron supplementation. , 2000, Blood.

[30]  W. C. O'Neill,et al.  Plasma pyrophosphate and vascular calcification in chronic kidney disease. , 2010, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[31]  J. Wernicke,et al.  The Kinetics and Mechanism of Iron (III) Exchange between Chelates and Transferrin IV. THE REACTION OF TRANSFERRIN WITH IRON(III) NITRILOTRIACETATE , 1971 .

[32]  A. Mason,et al.  Human serum transferrin: a tale of two lobes. Urea gel and steady state fluorescence analysis of recombinant transferrins as a function of pH, time, and the soluble portion of the transferrin receptor , 2009, JBIC Journal of Biological Inorganic Chemistry.

[33]  F. Polticelli,et al.  Ceruloplasmin-ferroportin system of iron traffic in vertebrates. , 2014, World journal of biological chemistry.

[34]  D. V. Van Wyck,et al.  Labile iron in parenteral iron formulations: a quantitative and comparative study. , 2004, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[35]  Ajay K. Singh,et al.  Ferric pyrophosphate citrate (Triferic™) administration via the dialysate maintains hemoglobin and iron balance in chronic hemodialysis patients , 2015, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[36]  D. Kosman,et al.  Ferroportin and Exocytoplasmic Ferroxidase Activity Are Required for Brain Microvascular Endothelial Cell Iron Efflux* , 2013, The Journal of Biological Chemistry.

[37]  S. Srichairatanakool,et al.  Non‐transferrin‐bound iron induced by myeloablative chemotherapy , 1997, British journal of haematology.

[38]  J. Małyszko,et al.  Iron metabolism in kidney allograft recipients: still a mystery? , 2011, Transplantation proceedings.

[39]  U. Çakatay,et al.  Human serum albumin and its relation with oxidative stress. , 2013, Clinical laboratory.

[40]  R. J. Hilton,et al.  Phosphate inhibits in vitro Fe3+ loading into transferrin by forming a soluble Fe(III)-phosphate complex: a potential non-transferrin bound iron species. , 2012, Journal of inorganic biochemistry.

[41]  K. Collard,et al.  Non-transferrin-bound iron is associated with biomarkers of oxidative stress, inflammation and endothelial dysfunction in type 2 diabetes. , 2015, Journal of diabetes and its complications.

[42]  R. Prabhu,et al.  Serum non-transferrin bound iron in hemodialysis patients not receiving intravenous iron. , 2005, Clinica chimica acta; international journal of clinical chemistry.

[43]  X. Correig,et al.  Metabolomics Approach for Analyzing the Effects of Exercise in Subjects with Type 1 Diabetes Mellitus , 2012, PloS one.

[44]  C. Rapisarda,et al.  Nature of non-transferrin-bound iron: studies on iron citrate complexes and thalassemic sera , 2007, JBIC Journal of Biological Inorganic Chemistry.

[45]  P. Brissot,et al.  Determination of non-transferrin-bound iron in genetic hemochromatosis using a new HPLC-based method. , 2000, Journal of hepatology.

[46]  Charles W Buffington,et al.  Human plasma ATP concentration. , 2007, Clinical chemistry.

[47]  D. Nelson,et al.  Comparing soluble ferric pyrophosphate to common iron salts and chelates as sources of bioavailable iron in a Caco-2 cell culture model. , 2009, Journal of agricultural and food chemistry.

[48]  C. Tseng Mortality and causes of death in a national sample of diabetic patients in Taiwan. , 2004, Diabetes care.

[49]  G. Sebastiani,et al.  Pharmacological Targeting of the Hepcidin/Ferroportin Axis , 2016, Front. Pharmacol..

[50]  P. Sadler,et al.  Non-transferrin-bound iron in plasma or serum from patients with idiopathic hemochromatosis. Characterization by high performance liquid chromatography and nuclear magnetic resonance spectroscopy. , 1989, The Journal of biological chemistry.

[51]  D. Kosman Iron metabolism in aerobes: managing ferric iron hydrolysis and ferrous iron autoxidation. , 2013, Coordination chemistry reviews.

[52]  C. Vulpe,et al.  Hephaestin is a ferroxidase that maintains partial activity in sex-linked anemia mice. , 2004, Blood.

[53]  Fu-Huang Lin,et al.  Intradialytic aerobic cycling exercise alleviates inflammation and improves endothelial progenitor cell count and bone density in hemodialysis patients , 2016, Medicine.

[54]  R. Hider Nature of nontransferrin‐bound iron , 2002, European journal of clinical investigation.

[55]  V. Carnevale,et al.  Studies on citrate metabolism in normal subjects and kidney stone patients. , 1989, Mineral and electrolyte metabolism.

[56]  Enzo Terreno,et al.  The extraordinary ligand binding properties of human serum albumin , 2005, IUBMB life.